Avastin vs eylea: which eye drug needs fewer shots?
NCT ID NCT04101877
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two drugs, Avastin and Eylea, given as eye injections for wet age-related macular degeneration (AMD). The main goal is to see which drug requires fewer injections over two years while still controlling the disease. Researchers will also check vision, eye thickness, and quality of life. About 402 people aged 50 and older with wet AMD are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab (Avastin) and aflibercept (Eylea)
What this could lead to
If it works, this could show which drug is more cost-effective and requires fewer injections for wet AMD, improving patient convenience and reducing treatment burden.
What could go wrong
This is a Phase 2 trial, so results are still early. The drugs may work similarly, or one might not be as effective as hoped. Risks include eye infection or inflammation from injections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vastra Gotaland Region, Sahlgrenska University Hospital, Department of Ophthalmology
Mölndal, Sweden